A panel of experts in multiple myeloma reviews key clinical trial data on the treatment of relapsed/refractory multiple myeloma (R/R MM) and discusses the best treatment approaches in the context of recent treatment approvals.
EP. 1: Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma (R/R MM)
Sagar Lonial, MD, FACP, provides an overview of the potential treatment options for patients with relapsed/refractory multiple myeloma.
EP. 2: Case 1: Treatment of R/R MM with a BCMA-Directed Bispecific Antibody
Dr Sagar Lonial presents the case of a 58-year-old man with relapsed/refractory multiple myeloma to the panel for discussion.
EP. 3: MajesTEC-1: Teclistamab in R/R MM Treatment
A look at BCMA targeting in relapsed/refractory multiple myeloma treatment and the BCMA-directed bispecific antibody teclistamab.
EP. 4: Selecting Patients with R/R MM for Treatment With Bispecifics
Krina Patel, MD, MSc, explains which patients with relapsed/refractory multiple myeloma she would not treat with CAR T-cell therapy, and the options after disease progression on CAR-T.
EP. 5: Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific
Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
EP. 6: Selecting an Appropriate BCMA-Directed Bispecific for Patients with R/R MM
The panel describes the factors they consider when selecting an appropriate BCMA-directed bispecific antibody for a patient with relapsed/refractory multiple myeloma.
EP. 7: DREAMM-2: Belantamab Mafodotin for the Treatment of R/R MM
Sagar Lonial, MD, FACP, reviews the design and outcomes of the DREAMM-2 and ALGONQUIN studies investigating belantamab mafodotin in the treatment of relapsed/refractory multiple myeloma.
EP. 8: Case 2: Treatment of R/R MM with BCMA-Directed CAR T-Cell Therapy
Hana Safah, MD, presents the case of a 63-year-old woman with relapsed/refractory multiple myeloma receiving treatment with a BCMA-directed CAR T-cell therapy.
EP. 9: CAR-T in R/R MM: Key Safety and Efficacy Data from the KarMMA and CARTITUDE-1 Trials
Dr Sagar Lonial highlights efficacy and safety data from the KarMMA and CARTITUDE-1 clinical trials.
EP. 10: Selecting the Appropriate CAR T-Cell Therapy in R/R MM
Drs Krina Patel and Hana Safah explain their impressions of the data on BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma and its potential impact on clinical practice.
EP. 11: Case 3: Sequencing BCMA-Directed Therapies for R/R MM
Krina Patel, MD, MSc, presents the case of a 65-year-old woman with relapsed/refractory multiple myeloma, and the panel discusses the optimal sequencing of her treatment regimens.
EP. 12: Unmet Needs in R/R MM and Clinical Practice Pearls
Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.
2 Commerce Drive Cranbury, NJ 08512